Vigonvita Life Sciences Co., Ltd. is a China-based biopharmaceutical company specializing in the discovery, development, and commercialization of small molecule drugs. It focuses on therapeutic areas including neuropsychiatric disorders, reproductive health, infectious diseases, cardio-cerebrovascular conditions, and oncology. The company maintains a fully integrated drug innovation system encompassing drug design and discovery, druggability assessment, preclinical and clinical research, pharmaceutical manufacturing, and market launch. Key products include MINDVY (VV116), an oral nucleoside prodrug approved for SARS-CoV-2 infections and under development for respiratory syncytial virus and human metapneumovirus, and ONVITA (TPN171) or Angweida (Simenafil Hydrochloride Tablets), a phosphodiesterase 5 inhibitor for erectile dysfunction and pulmonary arterial hypertension. Vigonvita operates manufacturing facilities compliant with GMP and EHS standards, including a modular emergency production platform, and conducts business in China and Uzbekistan while expanding into regions like North Africa, Central Asia, the Middle East, and Russia. Founded in 2013 and headquartered in Suzhou, it supports a competitive pipeline addressing unmet clinical needs in these fields.